Race, ethnicity, and use of thiazolidinediones among US adults with diabetes

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 489-494

  Aquilante, Christina L ^a   Zhang, Weiming ^a   McCollum, Marianne ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Diabetes mellitus; Health disparities; Pharmacoepidemiology; Race ethnicity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; GLIPIZIDE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG USE; ETHNICITY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; POVERTY; RACE DIFFERENCE; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 33947364295     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167354     Document Type: Article

References (28)

1. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-40
2. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004;140:945-50
3. Fan T, Koro CE, Fedder DO, Bowlin SJ. Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002. Diabetes Care 2006;29:1924-5
4. Lee JA, Liu CF, Sales AE. Racial and ethnic differences in diabetes care and health care use and costs. Prev Chronic Dis 2006;3:A85
5. Bonds DE, Zaccaro DJ, Karter AJ, et al. Ethnic and racial differences in diabetes care: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2003;26:1040-6
6. Saaddine JB, Engelgau MM, Beckles GL, et al. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565-74
7. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-8
8. Shaya FT, Shin JY, Muffins D, et al. Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin. J Natl Med Assoc 2005;97:493-7
9. Yki-Jarvinen H. Thiazolidinediones. New Engl J Med 2004;351:1106-18
10. Kendall DM. Thiazolidinediones: the case for early use. Diabetes Care 2006;29:154-7
11. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
12. Koski RR. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus. Diabetes Educ 2006;32:869-76
13. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004;27:982-91
14. Leiter LA. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabetic Med 2005;22:963-72
15. Umpierrez G, Dagogo-Jack S. Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations. Ethn Dis 2006;16:51-7
16. Haffner SM, D'Agostino R, Saad MF, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites [The Insulin Resistance Atherosclerosis Study]. Diabetes 1996;45:742-8
17. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003;52:2490-6
18. Agency for Healthcare Research and Quality, Rockville (MD). Medical Expenditure Panel Survey. MEPS Survey Background. http://207.188.212.220/ mepsweb/about_meps/survey_back.jsp [accessed December 5, 2006]
19. Agency for Healthcare Research and Quality, Rockville (MD). MEPS-HC Sample Design and Collection Process. http://www.meps.ahrq.gov/survey_comp/ hc_data_collection.jsp Accessed on December 5, 2006
20. United States Health Care Financing Administration: The international classification of diseases, 9th rev. Clinical modification: ICD-9-CM, 2nd ed. Washingtion (DC): US Dept. of Health and Human Services, Public Health, US Govt. Printing Office; 1980
21. Machlin, S, Yu, W, Zodet, M. Computing standard errors for MEPS estimates. Rockville (MD): Agency for Healthcare Research and Quality; January 2005
22. Mullins CD, Blatt L, Gbarayor CM, et al. Health disparities: a barrier to high-quality care. Am J Health-Syst Pharm 2005;62:1873-82
23. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta (GA): US Department of Heakh and Human Services, Centers for Disease Control and Prevention; 2005
24. Nelson KM, Chapko MK, Reiber G, Boyko EJ. The association between health insurance coverage and diabetes care; data from the 2000 Behavioral Risk Factor Surveillance System. Health Serv Res 2005;40:361-72
25. Roe CM, McNamara AM, Motheral BR. Gender- and age-related prescription drug use patterns. Ann Pharmacother 2002;36:30-9
26. Farley JF, Cline RR, Gupta K. Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). Osteoporosis Int 2006;17:395-404
27. Devine JW, Farley JF, Hadsall RS. Patterns and predictors of prescription medication use in the management of headache: findings from the 2000 Medical Expenditure Panel Survey. Headache 2005;45:1171-80
28. Kirby JB, Taliaferro G, Zuvekas SH. Explaining racial and ethnic disparities in health care. Med Care 2006;44:164-72